American Heart Journal
Volume 158, Issue 1 , Page e17 , July 2009

Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied

References 

  1. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352–360.e2
  2. Goti D, Hammer A, Galla HJ, et al. Uptake of lipoprotein-associated alpha-tocopherol by primary porcine brain capillary endothelial cells. J Neurochem. 2000;74:1374–1383
  3. Tachikawa M, Okayasu S, Hosoya K. Functional involvement of scavenger receptor class B, type I, in the uptake of alpha-tocopherol using cultured rat retinal capillary endothelial cells. Mol Vis. 2007;13:2041–2047
  4. Balazs Z, Panzenboeck U, Hammer A. Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J Neurochem. 2004;89:939–950
  5. van Dama B, van Hinsberghd VWM, Stehouwera CDA, et al. Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects. Cardiovasc Res. 2003;57:563–571
  6. Heller R, Werner-Felmayer G, Werner ER. Alpha-tocopherol and endothelial nitric oxide synthesis. Ann NY Acad Sci. 2004;1031:74–85
  7. Steinbrecher UP, Parthasarathy S, Leake DS, et al. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA. 1984;81:3883–3887
  8. Hackquebard M, Vandenbranden M, Malaisse WJ, et al. Transfer from lipid emulsions to plasma lipoproteins: mediation by multiple mechanisms. Lipids. 2008;43:663–671
  9. McKenney JM, Davidson MH, Shear CL. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll. Cardiol. 2006;48:1782–1790
  10. Barter PJ, Caulfield M, Eriksson M. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122

PII: S0002-8703(09)00351-2

doi: 10.1016/j.ahj.2009.05.001

American Heart Journal
Volume 158, Issue 1 , Page e17 , July 2009

Article Tools